Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice by Balsari, A et al.
Antineoplastic agents are currently not highly specific for cancer
cells and also damage normal cells. Indeed, chemotherapy affects
virtually every organ system in the body to an extent that depends
on the number of dividing cells (Goodman, 1989). Thus, tissues
that typically exhibit rapid cell turnover are the most sensitive to
the toxic effect of chemotherapy. Squamous epithelial cells of
gastrointestinal mucosa divide rapidly, with a cell generation time
of 12 to 24 h, and are therefore particularly vulnerable to the cyto-
toxicity of antineoplastic agents. The disruption in cell division
and maturation becomes histologically evident within 5 days of
drug exposure. As the damaged cells slough, the mucosa becomes
thin and denuded, accompanied by delayed cellular renewal,
mucosal atrophy, inflammation and often ulceration. The inci-
dence and severity of stomatitis or oral mucositis are highly
dependent on the therapy, i.e, the drug used, total dosage, drug
schedule, and concomitant therapy, and on the patient, i.e., tumour
type and age (Sonis, 1983). Patients who receive drugs such as
DXR or methotrexate can experience intense stomatitis. Patients
with hematological malignancies develop stomatitis two to three
times more frequently than do patients with solid tumors (Dreizen,
1978). Younger patients in whom cell renewal occurs more rapidly
are at greater risk for stomatitis, although they also heal more
quickly for the same reason. 
Grade 1 or 2 stomatitis usually resolves by 3 weeks, in time for
the next course of treatment. Moderate or severe (grade 3 or 4)
stomatitis that has not fully resolved at the time of retreatment
usually suggests not only a delay in treatment until the mucosa has
healed, but also a reduction in the drug dose. Moreover, stomatitis
in patients with severe granulocytopenia can lead to widespread
hematogenous bacterial dissemination since the oral lesions serve
as entry for the oral microflora to the bloodstream (Sonis, 1985).
Hospitalization is often necessary to maintain body hydration, to
control pain, and to prevent or manage infection. 
Of the approximately 50 drugs used in chemotherapy regimens,
DXR (Adriamycin®) has found one of the widest applications,
because of its activity against a broad range of malignancies. DXR
acts primarily at the DNA level through intercalation. The ability
of this drug to form covalent adducts with DNA has been corre-
lated to cellular apoptosis in tumor models (Zeman et al, 1998).
The pathogenesis of gastrointestinal injury induced by DXR has
been associated with the increase in intestinal apoptotic cells (Sun
et al, 1998). We have derived a murine monoclonal antibody
(Mab) against DXR which also reacts with other anthracycline
derivatives (Balsari et al, 1990). Topical application of this Mab to
the skin of rats prevents DXR-induced alopecia (Balsari et al,
1994). Moreover oral administration of the anti-DXR Mab
prevents chemotherapy-induced gastrointestinal toxicity in mice
(Morelli et al, 1996). 
In the present study, we show that anti-DXR monoclonal anti-
bodies, topically administered 2 h before i.v. injection of a high
dose of DXR, completely block DXR-induced oral apoptosis in an
animal model. Thus, anti-drug antibodies might provide a prophy-
lactic oral treatment to maintain the integrity of the oral mucosa. 
METHODS 
Mice 
Six- to eight-week-old female C57BI/6 mice were obtained from
Charles River (Calco, Italy). All mice were treated in accordance
with Institutional guidelines. Before sacrifice, mice were anaes-
thetized with 0.2 ml/20 g body weight of 10 mg/ml ketamine and
0.05% xylazine. 
Reagents 
Doxorubicin hydrochloride (Adriamycin) was supplied by
Pharmacia & Upjohn SpA (Milan, Italy). A fresh solution of DXR
was prepared just before use. The anti-DXR Mab MAD11 (IgG2a)
selectively recognizes epitopes located at or near the aromatic D
ring of the anthracycline molecule (Balsari et al, 1990). Ascitic
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fluids contained about 1 mg/ml of specific or unrelated antibody.
Human immunoglobulins (Sandoglobulina, Sandoz, Milan, Italy)
were used in immunohistochemistry experiments to avoid the
background reactivity on murine tissue due to the use of bio-
tinylated anti-murine IgG antibodies. 
Immunohistochemistry 
To evaluate immunoglobulin oral absorption, 200 µ l of human IgG
solution 50 mg/ml (Sandoz) were gently applied on oral mucosa of
3 mice using a micropipette. Two hours later mice were sacrificed,
tongues and cheeks removed and immersed in polyethylene-
glycol, frozen in vapor nitrogen and stored at –80˚C. The samples
were separated into 10 µ m parasagittal sections with a freeze
microtome at –25˚C and transferred to microscope slides. 
Sections were rehydrated with 1% bovine serum albumin in
PBS for 15 min at room temperature, fixed in 4% paraformalde-
hyde for 5 min at 4˚C and incubated overnight at 4˚C with anti-
human IgG peroxidated donkey IgG (Dako A/S, Glostrup,
Denmark) diluted 1:20. 
After rinsing in PBS, sections were blocked for endogenous
peroxidase activity with 0.3% hydrogen peroxide–PBS solution
for 40 min and incubated with diaminobenzidine (Sigma Chemical
Co., St. Louis, MO) for 5 min. The samples were observed with a
Nikon Eclipse 300 equipped with interference contrast. 
Induction of apoptosis by DXR 
Three groups of mice (3 animals/group) were treated i.v. with
16–22–30 mg/kg body weight of DXR respectively. Four hours
after treatment the animals were sacrificed, tongue removed and
immersed in polyethylene-glycol, frozen in vapor nitrogen and
preserved at –80˚C. The samples were parasagittal sectioned with
a cryostat obtaining 10 µ m thick sections and examined by
TUNEL assay, as described by Gavrieli et al (1992). Briefly,
terminal deoxyribonucleotyl-transferase (Boehringer Mannheim,
Mannheim, Germany) was used to insert FITC-conjugated
nucleotides (Boehringer Mannheim) at the 3′ ends of the DNA.
POD converter was used to detect FITC conjugated nucleotides and
the peroxidase was developed with diaminobenzidine (Sigma) for 5
min. The samples were observed with a Nikon Eclipse 300 equipped
with interference contrast. 
Effects of Mab MAD11 on DXR-induced apoptosis 
Ascitic fluid (400 µ l), containing anti-DXR Mab MAD11 or unre-
lated antibody, were gently applied to the oral mucosa of mice
(3 animals/group) using a micropipette. Two or 24 h later the
animals were treated i.v. with 30 mg/kg body weight of DXR. At
4, 8 and 24 h after DXR treatment mice were sacrificed, tongue
removed and examined by TUNEL as described above. 
RESULTS 
To verify oral mucosa permeability to immunoglobulin penetra-
tion, human immunoglobulins were gently painted onto murine
oral mucosa, and the painted tissue removed, sectioned and
immunohistochemically examined 2 h later. High level absorption
of immunoglobulins was observed on murine tongue, mainly at the
level of the tunica submucosa (Figure 1). By contrast, essentially
no immunoglobulin absorption was observed in the cheek mucosa
(data not shown), probably due to the high keratinization of this
tissue in mice. 
DXR induces cytotoxic effects on mouse small intestine cells,
predominantly in the base of the crypt. Typical apoptotic changes
are observed, such as nuclear and cytoplasmic condensation
and preservation of organelles in the early stages (Thakkar et al,
1992; Anilkumar et al, 1992). To evaluate DXR-induced apoptosis
in the oral cavity, mice were treated i.v. with DXR (16, 22
or 30 mg/kg body weight), sacrificed 4 h later, and tongues
were analyzed by TUNEL and microscopy. No apoptotic
cells were observed by TUNEL on tongues obtained from mice
treated with DXR at 16 or 22 mg/kg, whereas at 30 mg/kg
numerous basal layer cells of the tongue exhibited a positive
nuclear staining indicative of apoptosis (Figure 2). Apoptotic cells
were observed in specialized gustative and common epithelia. No
morphological alterations in sections of tongue were observed at
that time by microscopy, even at the dose of 30 mg/kg body weight
of DXR (data not shown). 
When 400 µ l of anti-DXR Mab MAD11 was gently applied to
murine tongue 2 h before i.v. injection of DXR (30 mg/kg body
weight), drug-induced apoptosis was completely prevented, as
evaluated 4, 8 and 24 h after anthracycline treatment (Figure
3B–3C). On the contrary apoptotic cells were present on tongues
obtained from mice treated with the unrelated antibody (Figure 3A).
When anti-DXR Mab MAD11 was applied 24 h before DXR treat-
ment, partial or no protection was observed (data not shown), indi-




Figure 1 Interference contrast photomicrographs of a parasagittal section
of murine tongue gently painted with saline buffer (A) or human
immunoglobulins (B). Bar 50 µ m 1966 A Balsari et al 
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DISCUSSION 
Histological examination of tongue samples from mice treated
with 30 mg/kg of DXR revealed numerous apoptotic cells, mainly
confined to the proliferative compartment of epithelium, which is
not surprising since cell proliferation occurs predominantly in the
basal two-thirds of the mucosa. 
DXR doses that induce cell apoptosis in the tongue are higher
than those that induce apoptosis in the intestinal mucosa (Morelli
et al, 1996). The higher responsiveness of intestinal mucosa is
perhaps due to the intestinal recycling of the drug that increases
the quantity of drug delivered to individual intestinal cells.
Because of the impossibility to evaluate mucositis in mice (Sonis
et al, 1990), apoptosis was considered as the end point for the toxic
activity of DXR. Indeed only hamster cheek pouch seems to be
sensitive to DXR-induced mucositis; in this model, modulation of
drug-induced mucositis was observed by topical administration of
transforming growth factor β that reduces cheek epithelial cell
proliferation (Sonis et al, 1994). 
Painting of the tongue with anti-DXR antibodies completely
inhibited DXR-induced apoptosis. The tongue surface is particularly
absorptive in general (Oyama et al, 1999; Purushotham et al, 1995),
so that a high concentration of blocking antibodies can be delivered
by topical administration. The efficacy of antibody administration at
2 h but not at 24 h before drug treatment indicates the rapid dilution
or degradation of the reagent in the mucosa. On the other hand, the
protection seems to be permanent since it was observed also at 24 h




Figure 2 Interference contrast photomicrographs of parasagittal sections of
murine tongue illustrating apoptosis induced by DXR. Mice were treated i.v.




Figure 3 Photomicrographs of parasagittal sections of murine tongue
illustrating protection from DXR-induced apoptosis. Mice were orally treated
with unrelated antibody (A), or with anti-anthracycline antibody (B–C), and
2 h later i.v. injected with 30 mg/kg of DXR. The tongues were evaluated
4 (A–B) or 24 (C) h later. Bar 100 µ m Prevention DXR-induced mouth apoptosis 1967
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Chemotherapy with high dose of anthracycline commonly
induces painful and dose-limiting oral mucositis. Oral treatment
with anti-DXR antibodies appears to be appropriate for patients
who develop mucositis after the first cycle of DXR therapy for
almost any tumor. The exception is oral cancer, where antibody
treatment might inhibit not only mucositis but also the drug activity
on the tumor cells. No side effects are expected from oral adminis-
tration of immunoglobulins, as suggested by many other observa-
tions (Tollemar et al, 1999; Johansson et al, 1999). 
In conclusion, simple oral administration of anthracycline anti-
body to prevent anthracycline-induced oral apoptosis may allow a
larger number of patients to tolerate high-dose chemotherapy. 
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